← Analyst Upside
AU · rank #4 · 2026-05-18
PRLD
NASDAQ · $356M
verdict · CAUTION
Why this pick · factor scores
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.755 |
| EPS revisions (30d) Net up-revisions in consensus EPS over the past month. | -83.33% |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $12,499,999 across 1 unique buyers. | 7.999 |
| Analyst upside Consensus target $6.88 | +53.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +10.51% |
| Analyst rating 1 = Strong Buy, 5 = Strong Sell. | 3.75 |
| Gross margin TTM | +100.0% |
| 52w high | $5.54 |
| Market cap | $356M |
AI research card
Independent qualitative review before order placement.
Summary
Prelude Therapeutics Inc. is a clinical-stage precision oncology company focused on discovering and developing novel small molecule therapies for cancer patients with high unmet needs.
Rationale
The significant analyst upside potential of 53.46% and strong insider buying activity suggest a belief in future stock appreciation despite recent negative EPS revisions.
Material risks
- 1As a clinical-stage biotechnology company, PRLD's success is highly dependent on the outcome of ongoing and future clinical trials for its drug candidates.
- 2The company has a limited cash runway, with existing funds anticipated to last into the second quarter of 2028, necessitating further financing or successful drug development.
Verdict reasoning
While analyst sentiment and insider buying are positive, the inherent risks of clinical-stage oncology development and limited cash runway warrant caution.